Today’s Price Action: Could Zynerba Pharmaceuticals Inc See a Reversal After This Very Strong Session?

Today's Price Action: Could Zynerba Pharmaceuticals Inc See a Reversal After This Very Strong Session?

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! About 171,132 shares traded hands. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 11.90% since April 5, 2016 and is uptrending. It has outperformed by 9.95% the S&P500.
The move comes after 6 months positive chart setup for the $119.68 million company. It was reported on Nov, 7 by We have $34.40 PT which if reached, will make NASDAQ:ZYNE worth $192.68 million more.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 9. They expect $-0.60 earnings per share, down 3.45% or $0.02 from last year’s $-0.58 per share. After $-0.70 actual earnings per share reported by Zynerba Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage

Out of 5 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 7 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Oppenheimer initiated the shares of ZYNE in a report on Tuesday, September 8 with “Outperform” rating. The stock has “Buy” rating given by Canaccord Genuity on Monday, September 14. The rating was initiated by Piper Jaffray on Monday, August 31 with “Overweight”. Jefferies initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Monday, August 31 with “Buy” rating. The firm earned “Buy” rating on Friday, October 7 by H.C. Wainwright. Oppenheimer maintained Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) rating on Thursday, November 12. Oppenheimer has “Outperform” rating and $34 price target.

According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”

Another recent and important Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) news was published by which published an article titled: “DOW JONES, A NEWS CORP COMPANY” on July 31, 2015.

ZYNE Company Profile

Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment